<strong>Background:</strong><span style="font-family:;" "=""> Aortic neo-cuspidization (AVNeo) procedure has been adopted by limited centers with </span><span style=...<strong>Background:</strong><span style="font-family:;" "=""> Aortic neo-cuspidization (AVNeo) procedure has been adopted by limited centers with </span><span style="font-family:;" "="">the </span><span style="font-family:;" "="">publication of the mid-long term successful resu<span>lts. The aim of this study was to present initial experience of the AVNeo pro</span>cedure of </span><span style="font-family:;" "="">a </span><span style="font-family:;" "="">single center.</span><span style="font-family:;" "=""> </span><b><span style="font-family:;" "="">Methods:</span></b><span style="font-family:;" "=""> The medical records of 24 patients who underwent AVNeo with or without concomitant cardiac surgery between February 2019 and February 2021 at our tertiary hospital were scanned retrospectively. <b>Results:</b> The mean age of patients was aged 58.21 ± 13.14 years an<span>d 16 (66.7%) of them were men. 16 patients were operated </span></span><span style="font-family:;" "="">on </span><span style="font-family:;" "="">for aortic steno</span><span style="font-family:;" "="">sis (66.67%). Morphology of the aortic valve was tricuspid in 21 (87.5%) and bi<span>cuspid in 3 (12.5%) of the patients. Additional cardicac surgery was performed </span>in 13 (54.17%) patients. No patients needed reoperation for bleeding, pace<span>maker implantations, conversion to classical prosthetic aortic valve replacement</span></span><span style="font-family:;" "="">,</span><span style="font-family:;" "=""> or infective endocarditis. Two patients died due to non-cardiac reasons</span><span style="font-family:;" "="">. Preoperative peak and mean aortic valve pressures improved significantly at 1<sup>st</sup> and 6<sup>th</sup> months (Preop:</span><span style="font-family:;" "=""> </span><span style="font-family:;" "="">89.06 ± 21.88 mmHg and 56.38 ± 15.09 mmH<span>g 1<sup>st</sup> month: 22.00 ± 3.93 mmHg and 8.73 ± 2.60 mmHg, 6<sup>th</sup> month: 18.13 </span>± 3.02 mmHg and 6.93 ± 1.83 mmHg)</span><span style="font-family:;" "="">. </span><b><span style="font-family:;" "="">Conclusion:</span></b><span style="font-family:;" "=""> In conclusion, the AVNe<span>o procedure is a feasible technique for aortic valve pathologies, with the adv</span>antages of avoiding anticoagulants and the applicability of concomitant surgic<span>al procedures. Although this procedure requires meticulous experience, res</span>ults similar to the available published literature can be obtained and reproducible even during learning curve when technical steps are strictly followed.</span>展开更多
文摘<strong>Background:</strong><span style="font-family:;" "=""> Aortic neo-cuspidization (AVNeo) procedure has been adopted by limited centers with </span><span style="font-family:;" "="">the </span><span style="font-family:;" "="">publication of the mid-long term successful resu<span>lts. The aim of this study was to present initial experience of the AVNeo pro</span>cedure of </span><span style="font-family:;" "="">a </span><span style="font-family:;" "="">single center.</span><span style="font-family:;" "=""> </span><b><span style="font-family:;" "="">Methods:</span></b><span style="font-family:;" "=""> The medical records of 24 patients who underwent AVNeo with or without concomitant cardiac surgery between February 2019 and February 2021 at our tertiary hospital were scanned retrospectively. <b>Results:</b> The mean age of patients was aged 58.21 ± 13.14 years an<span>d 16 (66.7%) of them were men. 16 patients were operated </span></span><span style="font-family:;" "="">on </span><span style="font-family:;" "="">for aortic steno</span><span style="font-family:;" "="">sis (66.67%). Morphology of the aortic valve was tricuspid in 21 (87.5%) and bi<span>cuspid in 3 (12.5%) of the patients. Additional cardicac surgery was performed </span>in 13 (54.17%) patients. No patients needed reoperation for bleeding, pace<span>maker implantations, conversion to classical prosthetic aortic valve replacement</span></span><span style="font-family:;" "="">,</span><span style="font-family:;" "=""> or infective endocarditis. Two patients died due to non-cardiac reasons</span><span style="font-family:;" "="">. Preoperative peak and mean aortic valve pressures improved significantly at 1<sup>st</sup> and 6<sup>th</sup> months (Preop:</span><span style="font-family:;" "=""> </span><span style="font-family:;" "="">89.06 ± 21.88 mmHg and 56.38 ± 15.09 mmH<span>g 1<sup>st</sup> month: 22.00 ± 3.93 mmHg and 8.73 ± 2.60 mmHg, 6<sup>th</sup> month: 18.13 </span>± 3.02 mmHg and 6.93 ± 1.83 mmHg)</span><span style="font-family:;" "="">. </span><b><span style="font-family:;" "="">Conclusion:</span></b><span style="font-family:;" "=""> In conclusion, the AVNe<span>o procedure is a feasible technique for aortic valve pathologies, with the adv</span>antages of avoiding anticoagulants and the applicability of concomitant surgic<span>al procedures. Although this procedure requires meticulous experience, res</span>ults similar to the available published literature can be obtained and reproducible even during learning curve when technical steps are strictly followed.</span>
